Comment
Author: Admin | 2025-04-28
Trazodone-induced priapism; however, it is widely known that trazodone is one of the medications most frequently associated with priapism: studies indicate that trazodone may be involved in nearly 80% of all cases of pharmacologically induced priapism (15).cNo cases or case reports of associated priapism were identified.++++=Very strong binding (inhibition constant [Ki] The most significant risk factor for developing priapism is a history of prolonged erections (2). Up to 50% of patients with priapism were found to have a history of delayed detumescence (1). In this report, we described a patient with a history of suspected trazodone-induced priapism, although ultimately, a definite cause could not be established. The patient was stable, without priapism, on multiple dual-antipsychotic regimens, including clozapine and chlorpromazine, and he subsequently experienced clozapine-induced priapism in the absence of trazodone. Several medical conditions have been implicated as risk factors for the development of priapism, including hematologic dyscrasias, infections, neurogenic disorders, neoplasms, and diabetes (1–3); however, laboratory workup results for these medical comorbidities were negative for our patient. Although patients may develop priapism at any time during the administration of antipsychotic medications, it frequently occurs after initiating medication administration or with subsequent changes in the dose (1). Polypharmacy may increase the likelihood of priapism through synergistic effects of the medications, particularly when patients are concurrently prescribed lithium and antipsychotics (lithium may increase antagonism of alpha-adrenergic receptors by antipsychotics) (1). However, our patient was not prescribed lithium nor any other agent likely to contribute to his priapism. On the basis of
Add Comment